Evaxion Biotech is an AI-immunology platform company decoding the immune system to discover and develop immunotherapies for cancer and other diseases.
Location: Denmark, Capital Region of Denmark, Hørsholm
Total raised: $67.6M
Founded date: 2008
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.06.2022 | - | $40M | - |
| 05.11.2021 | - | $27.6M | - |
Mentions in press and media 23
| Date | Title | Description |
| 05.06.2023 | Evaxion’s AI Technology Identifies Cancer Vaccine Targets Associated With Longer Progression-free Survival Of Melanoma Patients In The EVX-01 Phase 1 Clinical Trial | The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerability Positive clinical responses were reported in 8 out of 12 EVX-01 treated patients High-quality neoantigens, predicted by AI tec... |
| 15.04.2023 | Daily AI Roundup: Biggest Machine Learning, Robotic And Automation Updates 15th April 2023 | This is our AI Daily Roundup . We are covering the top updates from around the world. The updates will feature state-of-the-art capabilities in artificial intelligence (AI), Machine Learning, Robotic Process Automation, Fintech, and human-s... |
| 14.04.2023 | Evaxion And Pennsylvania State University Publish Preclinical Data Validating Our AI-based Viral Vaccine Discovery Platform | Evaxion Biotech A/S, a clinical-stage biotechnology company specializing in AI-powered immunotherapies, announces the successful publication in Frontiers of Immunology of preclinical data demonstrating the effectiveness of its proprietary A... |
| 23.03.2023 | Evaxion Presents A New Source Of AI-derived Immunotherapeutic Targets Strongly Associated With The Overall Survival Of Cancer Patients | Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapy This potentially enables treatment for patients with cold tumors, normally unresponsive to immunotherapy Evaxion Biotech A/S , a clinical-st... |
| 30.06.2022 | Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target | COPENHAGEN, Denmark, June 30, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced tha... |
| 23.06.2022 | Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer | COPENHAGEN, Denmark, June 23, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced tha... |
| 07.06.2022 | Evaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park Capital | COPENHAGEN, Denmark, June 07, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, announced today th... |
| 10.11.2021 | Evaxion Biotech Announces Closing of $27.6 Million Follow-on Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares | COPENHAGEN, Denmark, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives... |
| 09.11.2021 | Evaxion Biotech Announces Closing of $27.6 Million Follow-on Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares | COPENHAGEN, Denmark, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives... |
| 09.11.2021 | Evaxion Biotech Announces Q3 2021 Financial Results and Provides Business Update - Form 6-K | Evaxion Biotech Announces Q3 2021 Financial Results and Provides Business Update ● Expect to close our follow-on public offering (FPO) of 3,942,856 ordinary shares represented by American Depository Shares (ADSs) for gross proceeds of $27.6... |
Show more